Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Nova Mentis Life Science Corp. C.LIB

Nova Mentis Life Science Corp is a Canadian-based company focused on building and supporting a diversified portfolio of health and wellness businesses. Through its subsidiary, the company is focused on exploring the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes and providing a Health Canada Standard Licensed facility focused on the... see more

CSE:LIB - Post Discussion

Nova Mentis Life Science Corp. > Pet lovers. Lib better get off the pot.
View:
Post by RetiredGolfer on Jul 04, 2018 10:47am

Pet lovers. Lib better get off the pot.

https://www.680news.com/video/2018/07/03/cannabis-companies-preparing-for-pet-market/
Comment by TenFingers on Jul 04, 2018 11:39am
Yep - the window of opportunity will close as larger players corner this market as well. LIB needs to get moving. A news release on June 1, 2017 stated that the first trial would take 6-8 months. This actually would have been EXCELLENT timing if we could actually deliver anything on time. We would actually have a hand to play at this point as other licensed producers start devoting 10% or so of ...more  
Comment by Ovechkin on Jul 04, 2018 11:47am
This post has been removed in accordance with Community Policy
Comment by TenFingers on Jul 04, 2018 12:05pm
I've read the news. The mention of 6-8 months was in June, 2017.  The update in December gave no timeline details or re-confirmed timeline deails, only that they had a formula worked outand a hospital in France with some animals to test on. If you are arguing that this is on track with what they said, I beg to differ.
Comment by Ovechkin on Jul 04, 2018 12:32pm
This post has been removed in accordance with Community Policy
Comment by TenFingers on Jul 04, 2018 12:57pm
June 1, 2017: "The study will include large mixed-breed dogs, which will receive the drug or placebos in the active phase of study, with the timeline to finish the activity estimated at between six to eight months." I fully realize that they released news on December 20th (almost 7 monhts later) stating that the trials are starting. To me that doesn't change the wording above. I ...more  
Comment by Ovechkin on Jul 04, 2018 1:15pm
This post has been removed in accordance with Community Policy
Comment by TenFingers on Jul 04, 2018 3:09pm
I'm starting to wonder if we are reading the same thing at all... Very first paragraph (that you are referring to): "Vancouver, BC – June 1, 2017: Liberty Leaf Holdings Ltd. (CSE: LIB, OTCQB: LIBFF and FSE: HN3P) (the “Company” or “Liberty Leaf) announced today that it has finalized the statement of work model and design for testing the efficacy of ...more  
Comment by TenFingers on Jul 04, 2018 3:39pm
But all this cr@p aside, I am looking forward to seeing that upgrade completion and video of attestation first week of August, and clinical trial results hopefully by the same time. Need some love at this point, andsome fresh money coming in.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities